Santen Pharmaceutical Co., Ltd. (TYO:4536)

Market Cap	534.70B
Revenue (ttm)	293.97B
Net Income (ttm)	31.49B
Shares Out	327.03M
EPS (ttm)	91.41
PE Ratio	17.89
Forward PE	15.61
Dividend	38.00 (2.32%)
Ex-Dividend Date	Sep 29, 2025

Volume	1,489,100
Average Volume	1,359,915
Open	1,623.00
Previous Close	1,640.50
Day's Range	1,621.00 - 1,643.50
52-Week Range	1,310.50 - 1,872.50
Beta	0.17
RSI	52.92
Earnings Date	Nov 6, 2025

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; and ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prosta...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,849
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4536

Financial Performance

In 2024, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.